TODAY'S NEWS
The phase II CCTG CO.26 trial evaluated whether th...
Pembrolizumab significantly improved overall survi...
A phase II/III trial presented by Unno et al sough...
Anti–programmed cell death protein 1 and ant...
In a study reported in the Journal of the National...
More News From Today 
EDITORIALS & COMMENTARY
Trametinib is a MEK inhibitor approved both as a single agent and in combination with dabrafenib...
The treatment of breast cancer has been revolutionized by the development of HER2-targeted treatments...
Providing comprehensive chemotherapy education to patients in a busy clinical practice setting can be challenging...
Mr. S is a 39-year-old Hispanic male with a diagnosis of Philadelphia chromosome–negative ALL...
We would like to acknowledge everyone who completed peer reviews for JADPRO in the past year...
More Editorials & Commentary 
